Loading…

5PSQ-024 Hazard vulnerability analysis (HVA): evaluation of risk in experimental oncological drugs compounding

Background and ImportanceVarious clinical trials, especially in oncology and haematology, involve chemiotherapic drugs compounding. These preparations require standard working procedures for which hospital pharmacist is responsible. Oncological drugs used in clinical trials are characterised by: low...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2023-03, Vol.30 (Suppl 1), p.A119-A119
Main Authors: Cancellieri, G, Santonocito, M, de Luca, E, Botto, C, Giammona, R, Polidori, P
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and ImportanceVarious clinical trials, especially in oncology and haematology, involve chemiotherapic drugs compounding. These preparations require standard working procedures for which hospital pharmacist is responsible. Oncological drugs used in clinical trials are characterised by: low therapeutic index; unknown toxicity; dosage to be personalised on patient; assignment of number kit/placebo to specific patient; associations with other drugs not known in consolidated clinical practice. All these elements can contribute to the occurrence of potential errors.Aim and ObjectivesThe aim of this study is to used Hazard Vulnerability Analysis in order to classify, into high, medium, low risk, experimental protocols that provide for chemiotherapic drugs compounding and which are currently active our hospital. For protocols classified as high risk, standard procedures will be outlined to minimise risks.Material and MethodsIn order to determine the percentage risk(R%), is calculated: probability(P) that an error will occur, by calculating the number of preparation-phases; magnitude(MA) by calculating carcinogenicity, storage time of preparation and chemical incompatibility between drugs and medical devices; mitigation(MI) by calculating drug dosage, chemical-physical preparation stability, possible use of safety-devices. By applying the formula R%=(P/3)*[(MA+MI)/18]*100, protocols are defined low-risk if R%60%.ResultsAmong 35 active clinical-trials analysed, 18 require chemiotherapic drugs compounding. For 33%(6/18) of protocols the probability is low; 50%(9/18) is moderate; 17%(3/18) is high. For 44%(8/18) of protocols the magnitude is low; 50%(9/18) is moderate; 6%(1/18) is high. Finally, for 6%(1/18) of protocols the mitigation is low; 88%(16/18) is moderate; 6%(1/18) is high. By applying the formula to calculate percentage risk it was found that 5/18 protocols are low risk, 10/18 moderate risk, 3/18 high risk.Conclusion and RelevanceHVA provides a systematic approach to analysing hazards that may affect hospital service. Clinical protocols classified as ‘high risk’ have been monitored, and standard procedures have been outlined to minimise the risks (e.g. procedures for managing vial accidental breaking, cold chain control for prepared drugs, use of software to calculate drug dosage based on body surface). These procedures are aimed at all personnel involved in preparation phase, including the hosp
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2023-eahp.248